Login to Your Account

After early promise, CF101 blinks in dry eye

By Marie Powers
Staff Writer

Tuesday, December 31, 2013

Shares of Ophthalix Inc. (OTCQB:OPLI) swooned Monday after the company disclosed that CF101, an A3 adenosine receptor (A3AR) agonist licensed from parent company Can-Fite Biopharma Ltd., failed to meet primary and secondary efficacy endpoints in a Phase III study in moderate-to-severe dry eye syndrome (DES).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription